🏛️ Verified NIH Record • Updated 2026-07-08

A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NCT03779334)

An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Hoffmann-La Roche

🩺 Plain-English Summary (8th-Grade Level)

A global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).

Who can join: Review the eligibility criteria below.

Location: Nemours Children's Hospital — Orlando, Florida

Age range: 1 Day to 6 Weeks

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

  • Nemours Children's Hospital — Orlando, Florida
  • Sydney Children's Hospital — Randwick, New South Wales
  • Chr de La Citadelle — Liège,
  • Hospital das Clinicas - FMUSP_X — São Paulo, São Paulo
  • Szpital Gdanskiego Uniwersytetu Medycznego — Gda?sk,
  • Russian Children Neuromuscular Center of Veltischev — Moscow, Moscow Oblast
  • Kaohsiung Medical University Chung-Ho Hospital — Kaohsiung City,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗